Facebook
TwitterAttribution-ShareAlike 4.0 (CC BY-SA 4.0)https://creativecommons.org/licenses/by-sa/4.0/
License information was derived automatically
ChEMBL is maintained by the European Bioinformatics Institute (EBI), of the European Molecular Biology Laboratory (EMBL), based at the Wellcome Trust Genome Campus, Hinxton, UK.
ChEMBL is a manually curated database of bioactive molecules with drug-like properties used in drug discovery, including information about existing patented drugs.
Schema: http://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_23/chembl_23_schema.png
Documentation: http://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_23/schema_documentation.html
Fork this notebook to get started on accessing data in the BigQuery dataset using the BQhelper package to write SQL queries.
“ChEMBL” by the European Bioinformatics Institute (EMBL-EBI), used under CC BY-SA 3.0. Modifications have been made to add normalized publication numbers.
Data Origin: https://bigquery.cloud.google.com/dataset/patents-public-data:ebi_chembl
Facebook
TwitterAttribution-ShareAlike 3.0 (CC BY-SA 3.0)https://creativecommons.org/licenses/by-sa/3.0/
License information was derived automatically
Chemistry resources
Facebook
TwitterThe dataset used in this paper is the ChEMBL database, which contains drugs/molecules and their binding information for proteins Lyn, Lck, and Src.
Facebook
TwitterCollection of bioactive drug-like small molecules that contains 2D structures, calculated properties and abstracted bioactivities. Used for drug discovery and chemical biology research. Clinical progress of new compounds is continuously integrated into the database.
Facebook
TwitterThe ChEMBL database is a large collection of bioactive compounds and their biological activities.
Facebook
TwitterThis data package contains information on approved, researched and proven drug targets and drug lists.
Facebook
TwitterAttribution-ShareAlike 3.0 (CC BY-SA 3.0)https://creativecommons.org/licenses/by-sa/3.0/
License information was derived automatically
ChEMBL is a database of bioactive compounds, their quantitative properties and bioactivities (binding constants, pharmacology and ADMET, etc). The data is abstracted and curated from the primary scientific literature.
Facebook
TwitterAttribution-ShareAlike 3.0 (CC BY-SA 3.0)https://creativecommons.org/licenses/by-sa/3.0/
License information was derived automatically
This dataset contains curated molecular data for compounds tested against four pharmacologically important protein targets. All data are derived from the ChEMBL database.
| Target Name | ChEMBL Target ID | Target Class |
|---|---|---|
| EGFR | CHEMBL203 | Kinase (Receptor TK) |
| DRD2 | CHEMBL217 | GPCR (Dopamine D2 receptor) |
| BACE1 | CHEMBL1987 | Enzyme (Aspartyl protease) |
| HDAC1 | CHEMBL325 | Enzyme (Histone deacetylase) |
Each entry in the dataset includes: - ChEMBL compound ID - Canonical SMILES - Molecular properties (molecular weight, HBA, HBD, logP, and TPSA) - Target label
The dataset is provided in CSV or Parquet format with the following columns:
ChEMBL ID: ChEMBL compound identifierSMILES: Canonical SMILES stringMolecular weight: Molecular mass (Da)LogP: Octanol-water partition coefficientHBA: Number of hydrogen bond acceptorsHBD: Number of hydrogen bond donorsTPSA: Topological polar surface areaProtein: Protein target nameThis dataset is a derivative of ChEMBL and is distributed under the same license:
Creative Commons Attribution-ShareAlike 3.0 Unported (CC BY-SA 3.0)
https://creativecommons.org/licenses/by-sa/3.0/
chembl_webresource_client)If you use this dataset, please cite the following:
ChEMBL Database:
Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, Mutowo P, Atkinson F, Bellis LJ, Cibrián-Uhalte E, Davies M, Dedman N, Karlsson A, Magariños MP, Overington JP, Papadatos G, Smit I, Leach AR. (2017).
The ChEMBL database in 2017. Nucleic Acids Res., 45(D1): D945–D954.
https://doi.org/10.1093/nar/gkw1074
ChEMBL Web Services:
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis LJ, Overington JP. (2015).
ChEMBL web services: streamlining access to drug discovery data and utilities. Nucleic Acids Res., 43(W1): W612–W620.
https://doi.org/10.1093/nar/gkv352
Facebook
TwitterAttribution-NonCommercial 4.0 (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/
License information was derived automatically
A detailed analysis of the hERG content inside the ChEMBL database is performed. The correlation between the outcome from binding assays and functional assays is probed. On the basis of descriptor distributions, design paradigms with respect to structural and physicochemical properties of hERG active and hERG inactive compounds are challenged. Finally, classification models with different data sets are trained. All source code is provided, which is based on the Python open source packages RDKit and scikit-learn to enable the community to rerun the experiments. The code is stored on github (https://github.com/pzc/herg_chembl_jcim).
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Information
The diverse publicly available compound/bioactivity databases constitute a key resource for data-driven applications in chemogenomics and drug design. Analysis of their coverage of compound entries and biological targets revealed considerable differences, however, suggesting benefit of a consensus dataset. Therefore, we have combined and curated information from five esteemed databases (ChEMBL, PubChem, BindingDB, IUPHAR/BPS and Probes&Drugs) to assemble a consensus compound/bioactivity dataset comprising 1144803 compounds with 10915362 bioactivities on 5613 targets (including defined macromolecular targets as well as cell-lines and phenotypic readouts). It also provides simplified information on assay types underlying the bioactivity data and on bioactivity confidence by comparing data from different sources. We have unified the source databases, brought them into a common format and combined them, enabling an ease for generic uses in multiple applications such as chemogenomics and data-driven drug design.
The consensus dataset provides increased target coverage and contains a higher number of molecules compared to the source databases which is also evident from a larger number of scaffolds. These features render the consensus dataset a valuable tool for machine learning and other data-driven applications in (de novo) drug design and bioactivity prediction. The increased chemical and bioactivity coverage of the consensus dataset may improve robustness of such models compared to the single source databases. In addition, semi-automated structure and bioactivity annotation checks with flags for divergent data from different sources may help data selection and further accurate curation.
Structure and content of the dataset
|
ChEMBL ID |
PubChem ID |
IUPHAR ID | Target |
Activity type | Assay type | Unit | Mean C (0) | ... | Mean PC (0) | ... | Mean B (0) | ... | Mean I (0) | ... | Mean PD (0) | ... | Activity check annotation | Ligand names | Canonical SMILES C | ... | Structure check | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The dataset was created using the Konstanz Information Miner (KNIME) (https://www.knime.com/) and was exported as a CSV-file and a compressed CSV-file.
Except for the canonical SMILES columns, all columns are filled with the datatype ‘string’. The datatype for the canonical SMILES columns is the smiles-format. We recommend the File Reader node for using the dataset in KNIME. With the help of this node the data types of the columns can be adjusted exactly. In addition, only this node can read the compressed format.
Column content:
Facebook
TwitterAttribution-NonCommercial 4.0 (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/
License information was derived automatically
A systematic analysis is presented of the 220 phosphodiesterase (PDE) catalytic domain crystal structures present in the Protein Data Bank (PDB) with a focus on PDE–ligand interactions. The consistent structural alignment of 57 PDE ligand binding site residues enables the systematic analysis of PDE–ligand interaction fingerprints (IFPs), the identification of subtype-specific PDE–ligand interaction features, and the classification of ligands according to their binding modes. We illustrate how systematic mining of this phosphodiesterase structure and ligand interaction annotated (PDEStrIAn) database provides new insights into how conserved and selective PDE interaction hot spots can accommodate the large diversity of chemical scaffolds in PDE ligands. A substructure analysis of the cocrystallized PDE ligands in combination with those in the ChEMBL database provides a toolbox for scaffold hopping and ligand design. These analyses lead to an improved understanding of the structural requirements of PDE binding that will be useful in future drug discovery studies.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Discovery of new pharmaceutical substances is currently boosted by the possibility of utilization of the Synthetically Accessible Virtual Inventory (SAVI) library, which includes about 283 million molecules, each annotated with a proposed synthetic one-step route from commercially available starting materials. The SAVI database is well-suited for ligand-based methods of virtual screening to select molecules for experimental testing. In this study, we compare the performance of three approaches for the analysis of structure-activity relationships that differ in their criteria for selecting of “active” and “inactive” compounds included in the training sets. PASS (Prediction of Activity Spectra for Substances), which is based on a modified Naïve Bayes algorithm, was applied since it had been shown to be robust and to provide good predictions of many biological activities based on just the structural formula of a compound even if the information in the training set is incomplete. We used different subsets of kinase inhibitors for this case study because many data are currently available on this important class of drug-like molecules. Based on the subsets of kinase inhibitors extracted from the ChEMBL 20 database we performed the PASS training, and then applied the model to ChEMBL 23 compounds not yet present in ChEMBL 20 to identify novel kinase inhibitors. As one may expect, the best prediction accuracy was obtained if only the experimentally confirmed active and inactive compounds for distinct kinases in the training procedure were used. However, for some kinases, reasonable results were obtained even if we used merged training sets, in which we designated as inactives the compounds not tested against the particular kinase. Thus, depending on the availability of data for a particular biological activity, one may choose the first or the second approach for creating ligand-based computational tools to achieve the best possible results in virtual screening.
Facebook
TwitterThe safety of marketed drugs is an ongoing concern, with some of the more frequently prescribed medicines resulting in serious or life-threatening adverse effects in some patients. Safety-related information for approved drugs has been curated to include the assignment of toxicity class(es) based on their withdrawn status and/or black box warning information described on medicinal product labels. The ChEMBL resource contains a wide range of bioactivity data types, from early “Discovery” stage preclinical data for individual compounds through to postclinical data on marketed drugs; the inclusion of the curated drug safety data set within this framework can support a wide range of safety-related drug discovery questions. The curated drug safety data set will be made freely available through ChEMBL and updated in future database releases.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Reported is the activity information for the 12,294 analog series-based (ASB) scaffolds extracted from ChEMBL database. For each ASB scaffold structural and activity information for all analogs comprising the analog series is provoded.
Facebook
TwitterAttribution-NonCommercial-ShareAlike 4.0 (CC BY-NC-SA 4.0)https://creativecommons.org/licenses/by-nc-sa/4.0/
License information was derived automatically
This dataset contains bioactivity, toxicity, and druglikeness information of 28314 small compounds, obtained from the ChEMBL database and subsequently curated, targeting tyrosine kinases proteins. It is comprised of the following elements:
The data can be used to train models that predict or classify bioactivity and druglike properties of small compounds targeting a tyrosine kinase protein.
Facebook
TwitterAttribution 3.0 (CC BY 3.0)https://creativecommons.org/licenses/by/3.0/
License information was derived automatically
SMILES (simplified molecular-input line-entry system) strings are ASCII sequences that describe the structure of a compound. Due to their simplicity, SMILES representations have been widely used in drug design, mining, and repurposing using machine learning and natural language processing techniques.
See Cheminformania's seq2seq model for an excellent tutorial to get started.
A single text file
Each row contains two columns for description of an individual molecule. The first column is the SMILES string. The second is a reference to the full ChEMBL entry for that particular molecule.
ChEMBL Database: Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, Mutowo P, Atkinson F, Bellis LJ, Cibrián-Uhalte E, Davies M, Dedman N, Karlsson A, Magariños MP, Overington JP, Papadatos G, Smit I, Leach AR. (2017) 'The ChEMBL database in 2017.' Nucleic Acids Res., 45(D1) D945-D954.
ChEMBL Web Services: Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1) W612-W620.
ChEMBL RDF: S. Jupp, J. Malone, J. Bolleman, M. Brandizi, M. Davies, L. Garcia, A. Gaulton, S. Gehant, C. Laibe, N. Redaschi, S.M Wimalaratne, M. Martin, N. Le Novère, H. Parkinson, E. Birney and A.M Jenkinson (2014) The EBI RDF Platform: Linked Open Data for the Life Sciences Bioinformatics 30 1338-1339
Facebook
Twitterhttps://creativecommons.org/publicdomain/zero/1.0/https://creativecommons.org/publicdomain/zero/1.0/
I have spent some time scrapping and shaping PubChem data into a Neo4j graph database. The process took a lot of time, mainly downloading, and loading it into Neo4j. The whole process took weeks. If you want to build your own I will show you how to download mine and set it up in less than an hour (most of the time you’ll just have to wait). The process of how this dataset is created is described in the following blogs: - https://medium.com/@nijhof.dns/exploring-neodash-for-197m-chemical-full-text-graph-e3baed9615b8 - https://medium.com/neo4j/combining-3-biochemical-datasets-in-a-graph-database-8e9aafbb5788 - https://medium.com/p/d9ee9779dfbe
The full database is a merge of 3 datasets, PubChem (compounds + synonyms), NCI60 (GI50), and ChEMBL (cell lines). It contains 6 nodes of interest: ● Compound: This is related to a compound of PubChem. It has 1 property. ○ pubChemCompId: The id within pubchem. So “compound:cid162366967” links to https://pubchem.ncbi.nlm.nih.gov/compound/162366967. This number can be used with both PubChem RDF and PUG. ● Synonym: A name found in the literature. This name can refer to zero, one, or more compounds. This helps find relations between natural language names and absolute compounds they are related to. ○ Name: Natural language name. Can contain letters, spaces, numbers, and any other Unicode character. ○ pubChemSynId: PubChem synonym id as used within the RDF ● CellLine: These are the ChEMBL cell lines. They hold a lot of information. ○ Name: The name of the cell line. ○ Uri: A unique URI for every element within the ChEMBL RDF. ○ cellosaurusId: The id to connect it to the Cellosaurus dataset. This is one of the most extensive cell line datasets out there. ● Measurement: A measurement you can do within a biomedical experiment. Currently, only GI50 (the concentration needed for Growth Inhibition of 50%) is added. ○ Name: Name of the measurement. ● Condition: A single condition of an experiment. A condition is part of an experiment. Examples are: an individual of the control group, a sample with drug A, or a sample with more CO2 ● Experiment: A collection of multiple conditions all done at the same time with the same bias. Meaning we assume all uncontrolled variables are the same. ○ Name: Name of experiment.
https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F442733%2F7dd804811e105390dfe20bb5cd1a68c0%2FUntitled%20graph.png?generation=1680113457794452&alt=media" alt="">
How do download it Warning, you need 120 GB of free memory. The compressed file you download is already 30 GB. The uncompressed file is 30 GB. The database afterward is 60 GB. 60 GB is only for temporary files, the other 60 is for the database. If you do this on an HDD hard disk it will be slow.
If you load this into Neo4j desktop as a local database (like I do) it will scream and yell at you, just ignore this. We are pushing it far further than it is designed for, but it will still work.
Go to this Kaggle dataset and download the dump file. Unzip the file, then delete the zipped file. This part needs 60 GB but only takes 30 by the end of it.
Create a database
Open the Neo4j desktop app, and click “Reveal files in File Explorer”. Move the .dump you downloaded into this folder.
Click on the ... behind the .dump file and click Create new DBMS from dump. This database is a dump from Neo4j V4, so your database also needs to be V4.x.x!
It will now create the database. This will take a long time, it might even say it has timed out. Do not believe this lie! In the background, it is still running. Every time you start it, it will time out. Just let it run and press start later again. The second time it will be started up directly.
Every time I start it up I get the timed-out error. After waiting 10 minutes and clicking start again the database, and with it, more than 200 million nodes, is ready. And you are done! Good luck and let me know what you build with it
Facebook
TwitterMIT Licensehttps://opensource.org/licenses/MIT
License information was derived automatically
KinFragLib: Exploring the Kinase Inhibitor Space Using Subpocket-Focused Fragmentation and Recombination.
Project description.
Protein kinases play a crucial role in many cell signaling processes, making them one of the most important families of drug targets. In this context, fragment-based drug design strategies have been successfully applied to develop novel kinase inhibitors, usually following a knowledge-driven approach to optimize a focused set of fragments to a potent kinase inhibitor.
Alternatively, KinFragLib is a new method that allows to explore and extend the chemical space of kinase inhibitors using data-driven fragmentation and recombination, built on available structural kinome data from the KLIFS database for over 3,200 kinase DFG-in complexes. The computational fragmentation method splits the co-crystallized non-covalent kinase inhibitors into fragments with respect to their 3D proximity to six predefined functionally relevant subpocket centers. The resulting fragment library consists of six subpocket pools with over 9,000 fragments, available at https://github.com/volkamerlab/KinFragLib.
KinFragLib offers two main applications: (i) In-depth analyses of the chemical space of known kinase inhibitors, subpocket characteristics and connections, as well as (ii) subpocket-informed recombination of fragments to generate potential novel inhibitors. The latter showed that recombining only a subset of 727 representative fragments generated a combinatorial library of 11.3 million molecules, containing, besides some known kinase inhibitors, more than 99% novel chemical matter compared to ChEMBL and 55% molecules compliant with Lipinski's rule of five.
Combinatorial library dataset.
The dataset offered here is part of the KinFragLib GitHub repository (https://github.com/volkamerlab/KinFragLib) and contains the metadata and properties of the KinFragLib combinatorial library.
combinatorial_library.json: Full combinatorial library, please refer to notebooks/4_1_combinatorial_library_data_preparation.ipynb at https://github.com/volkamerlab/KinFragLib for detailed information about this data format.
combinatorial_library_deduplicated.json: Deduplicated combinatorial library (based on InChIs).
chembl_standardized_inchi.csv: Standardized ChEMBL 33 molecules in the form of InChI strings.
Data extracted from combinatorial_library_deduplicated.json, performed in notebooks/4_1_combinatorial_library_data_preparation.ipynb at https://github.com/volkamerlab/KinFragLib.
n_atoms.csv: Number of atoms for each recombined ligand.
ro5.csv: Number of ligands that fulfill Lipinski's rule of five (Ro5) and its individual criteria; number of ligands in total.
subpockets.csv: Number of ligands per subpocket combination.
original_exact.json: Ligands with exact matches in original ligands, i.e. KLIFS ligands that were used for the fragmentation.
original_substructure.json: Ligands with substructure matches in original ligands, i.e. KLIFS ligands that were used for the fragmentation.
chembl_exact.json: Ligands with exact matches in ChEMBL.
chembl_most_similar.json: Most similar ligand in ChEMBL for each recombined ligand.
chembl_highly_similar.json: Most similar ligand in ChEMBL for each recombined ligand with similarity greater than 0.9.
Usage.
This dataset can be used to run the notebooks available on https://github.com/volkamerlab/KinFragLib.
Clone the KinFragLib repository.
Download the tar.bz2 file provided here.
Extract the archive content to the combinatorial library folder in your local KinFragLib folder and run the notebooks.
tar -xvf combinatorial_library.tar.bz2 -C /path_to_kinfraglib/data/combinatorial_library/
Citation.
This dataset is part of the KinFragLib publication:
Sydow, D., Schmiel, P., Mortier, J., and Volkamer, A. KinFragLib: Exploring the Kinase Inhibitor Space Using Subpocket-Focused Fragmentation and Recombination. J. Chem. Inf. Model. 2020. https://pubs.acs.org/doi/abs/10.1021/acs.jcim.0c00839
Facebook
TwitterChEMBL Data is a manually curated database of small molecules used in drug discovery, including information about existing patented drugs.
Facebook
TwitterAmong all 270,540 drug-protein pairs from the ChEMBL data set, the top 50 unknown pairs determined by the KL1LR method using data sets were checked, and the unknown pair was listed if it was found in the STITCH [4], DrugBank [1], KEGG [2], BindingDB [36], and CTD [35] data sets. Drugs in the second column and proteins in the third column are likely to interact, based on the probabilities shown in the fourth column. If interactions are found in more than two data sets, only one source is listed. Similarly, the results obtained using chemical structure similarities are shown.
Facebook
TwitterAttribution-ShareAlike 4.0 (CC BY-SA 4.0)https://creativecommons.org/licenses/by-sa/4.0/
License information was derived automatically
ChEMBL is maintained by the European Bioinformatics Institute (EBI), of the European Molecular Biology Laboratory (EMBL), based at the Wellcome Trust Genome Campus, Hinxton, UK.
ChEMBL is a manually curated database of bioactive molecules with drug-like properties used in drug discovery, including information about existing patented drugs.
Schema: http://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_23/chembl_23_schema.png
Documentation: http://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_23/schema_documentation.html
Fork this notebook to get started on accessing data in the BigQuery dataset using the BQhelper package to write SQL queries.
“ChEMBL” by the European Bioinformatics Institute (EMBL-EBI), used under CC BY-SA 3.0. Modifications have been made to add normalized publication numbers.
Data Origin: https://bigquery.cloud.google.com/dataset/patents-public-data:ebi_chembl